BioStar files for rapid influenza test:
This article was originally published in Clinica
US firm BioStar has filed a 510(k) application with the FDA to market a rapid diagnostic for influenza which detects two types of the virus (A and B) simultaneously. Developed with Australian firm Biota Holdings, the test takes around 15 minutes to perform and needs no instrumentation. Boulder, Colorado-based BioStar said sales will be limited until the launch of Biota's anti-flu drug Relenza.